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ABSTRACT 
 Botulinum neurotoxins (BoNTs) are responsible for severe flaccid paralysis (botulism) 
which in most cases enter the organism via the digestive tract and then disseminate into the 
blood or lymph circulation to target autonomic and motor nerve endings. The passage way of 
BoNTs alone or in complex forms with associated non-toxic proteins through the epithelial 
barrier of the digestive tract still remains unclear. Here we show using an in vivo model of 
mouse ligated intestinal loop that BoNT/B alone or the BoNT/B C-terminal domain of the 
heavy chain (HCcB), which interacts with cell surface receptors, translocate across the 
intestinal barrier. The BoNT/B or HCcB translocation through the intestinal barrier occurred 
via an endocytosis-dependent mechanism within 10-20 min, since Dynasore, a potent 
endocytosis inhibitor, significantly prevented BoNT/B as well as HCcB translocation. We 
also show that HCcB or BoNT/B specifically target neuronal cells and neuronal extensions in 
the intestinal submucosa and musculosa expressing synaptotagmin, preferentially cholinergic 
neurons and to a lower extent other neuronal cell types, notably serotoninergic neurons. 
Interestingly, rare intestinal epithelial cells accumulated HCcB suggesting that distinct cell 
types of the intestinal epithelium, still undefined, might mediate efficient translocation of 
BoNT/B. 
 
 
INTRODUCTION 
 Clostridium botulinum produces potent neurotoxins (botulinum neurotoxins, BoNTs) 
which are responsible for severe neuroparalytic illness (botulism) in man and animals 
resulting from inhibition of spontaneous and nerve-evoked acetylcholine (ACh) release at 
cholinergic nerve endings. BoNTs are synthesized as an inactive single protein (~150 kDa) 
that is proteolytically cleaved into a ~100 kDa heavy chain (HC) and a ~50 kDa light chain 
(LC). Both chains remain linked by a disulfide bridge. The di-chain molecule constitutes the 
active neurotoxin. The half C-terminal part of HC (HCc) recognizes specific receptors on the 
surface of target neuronal cells and is involved in driving the toxin entry pathway into cells, 
whereas the N-terminal part permits the translocation of the L chain into the cytosol. LC 
catalyzes a zinc-dependent proteolysis of one or two of the three proteins of the SNARE 
complex, which play an essential role in neurotransmitter exocytosis (Meunier et al., 2002, 
Poulain et al., 2008, Bercsenyi et al., 2013, Simpson, 2013, Rossetto et al., 2014). 
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 BoNTs are divided into 7 toxinotypes (A to G) according to their immunological 
properties based on neutralization with polyclonal antibodies. Each toxinotype is specifically 
neutralized only with the corresponding antibodies (Hill et al., 2013). A new toxinotype 
called H or rather a new hybrid F/A type has been recently reported but still needs further 
characterization (Dover et al., 2014, Gonzalez-Escalona et al., 2014). C. botulinum strains 
show genetic variations and are classified into 4 groups (I to IV) based on 16s rRNA gene 
sequences and biochemical characteristics. Most of the strains produce only one BoNT type. 
Genetic diversity is also observed in bont genes, and multiple subtypes (or genetic variants) 
have been identified in each BoNT toxinotype (reviewed in (Hill et al., 2013)). 
 Three forms of botulism are recognized in humans in natural conditions: foodborne 
botulism, infant botulism or botulism by intestinal colonization, and wound botulism. 
Foodborne botulism is due to the ingestion of preformed BoNT in contaminated food and it is 
the main form of botulism in adults. In contrast, in infant botulism and some adult cases, 
ingested C. botulinum spores develop in the intestinal content and produce the toxin in situ 
(Tacket et al., 1989, Sobel, 2005). In both forms, foodborne botulism and botulism by 
intestinal colonization, BoNT escapes the gastro-intestinal tract to reach the target cholinergic 
nerve endings, possibly through the blood and lymph circulation (Maksymowych et al., 
1999). Previous observations using experimental models of animal intoxination have shown 
that following oral administration, BoNT enters the blood stream and lymph circulation 
(Maksymowych et al., 1999). The upper small intestine was found to be the primary site of 
toxin absorption (Kitamura et al., 1969, Sugii et al., 1977, Bonventre, 1979, Fujinaga et al., 
1997). However, BoNT can also be absorbed from the other parts of the digestive tract 
including the buccal cavity, stomach and colon, but to a lower extent than in the upper small 
intestine (Bonventre, 1979, Sakaguchi, 1983, Maksymowych et al., 1999). Therefore, BoNT 
translocation through the intestinal barrier and trafficking to the cholinergic nerve ending 
target represent the initial and critical steps of botulinum intoxination.  
 The mechanism of BoNT passage through the intestinal epithelial barrier remains 
partially unknown. Botulinum complexes formed by BoNT and associated non-toxic proteins 
(ANTPs) including hemagglutinin (HA) components have reported to pass across the 
epithelial barrier upon HA-mediated opening of intercellular junctions. Indeed, HA subunits 
have been shown to bind to epithelial cadherin (E-cadherin) and to disrupt the intercellular 
junctional complexes between epithelial cells (Jin et al., 2009, Sugawara et al., 2010, 
Sugawara et al., 2011, Lee et al., 2014, Lam et al., 2015). However, purified BoNT has also 
been shown to undergo transcytosis through intestinal epithelial cells without the help of HAs 
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(Fujinaga et al., 1997, Maksymowych et al., 1998, Park et al., 2003, Maksymowych et al., 
2004, Nishikawa et al., 2004, Ahsan et al., 2005, Couesnon et al., 2008). BoNT/A seems to 
preferentially use specific subsets of intestinal cells such as crypt enteroendocrine cells to 
enter the intestinal mucosa (Couesnon et al., 2012). In this study, we investigated the passage 
of BoNT/B in the mouse intestinal mucosa since it is a major cause of foodborne botulism and 
infant botulism in various countries (Fox et al., 2005, Peck, 2009, Malaska, 2014, Mazuet et 
al., 2014).  
 
RESULTS 
 
Entry of HCc/B into the mouse intestinal mucosa 
 Recombinant HCc from BoNT/B (HCc/B) labeled with Cy3 has been used to monitor 
BoNT/B entry into mouse intestinal mucosa. HCc domain of clostridial neurotoxins (BoNTs 
and tetanus neurotoxin), which specifically interacts with cell receptors, has already been 
extensively used to investigate internalization and intracellular trafficking of the neurotoxins 
in neuronal cells, as well as toxin translocation through intestinal epithelial cells (Lalli et al., 
2003, Maksymowych et al., 2004, Bohnert et al., 2005, Roux et al., 2006, Harper et al., 2011, 
Restani et al., 2012, Lam et al., 2015). Similar strategy was performed in the analysis of 
BoNT/A passage through the mouse intestinal mucosa (Couesnon et al., 2012). Therefore, 
fluorescent HCcB was injected into ligated ileum loops of anesthetized mice. The animals 
were then killed at various time intervals and the intestinal loops were washed, fixed and 
prepared for confocal microscopy observations. As shown in Fig. 1A (upper panel) limited 
HCcB fluorescence was observed in the intestinal lumen between the villi after 5 min 
incubation. Strikingly, rare epithelial cells of the villi accumulated fluorescent HCcB (Fig. 
1A, middle panel). A few filamentous structures labeled with HCcB were also detected in 
some intestinal villi and in some submucosa areas (Fig. 1A, lower panel). After 10 and 20 min 
incubation, labeled HCcB was visualized in the inter-villi spaces, the lumen of intestinal 
crypts, and on the surface of some intestinal villi, but no HCcB staining was evidenced in 
crypt epithelial cells (Fig. 1B, upper and middle panels, Fig. 1C, upper panel). Again, only 
very few cells of the villus epithelium were stained with HCcB (Fig. 1B and 1C upper 
panels). Filamentous elements stained with HCcB were observed in the bottom of intestinal 
villi surrounding intestinal crypts (Fig. 1B, middle panel and Fig. 1C, upper and middle 
panels). A dense network of filamentous structures in the musculosa was stained with 
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fluorescent HCcB (Fig. 1B lower panel, Fig. 1C, upper and lower panels). In addition, 
fluorescent filament structures were also evidenced inside the core of the villi (Fig. 1A middle 
panel, Fig. 1B upper panel). The most marked observations were the abundant filament 
labeling in the submucosa and to a larger extent in the musculosa after 10 and 20 min 
incubation of the ileal loops with fluorescent HCcB (Fig. 1B lower panel, Fig. 1C, upper and 
lower panels). Albeit the in vivo experiments at different incubation time periods did not 
allow to determine a precise kinetics of the toxin passage through the intestinal barrier, they 
permitted to evidence the progressive translocation of HCcB lasting 5 to 20 min from the 
intestinal lumen to target structures in the submucosa and musculosa. This finding was further 
supported by the quantification of the HCcB fluorescence intensity showing HCcB 
accumulation in villi overtime, and entry into the submucosa/musculosa at 10-20 min (Fig. 
1C). 
 
Dynasore impairs the translocation of HCcB into the intestinal mucosa  
 BoNT/A has been evidenced to cross the epithelial barrier through a transcytotic 
mechanism in the absence of ANTPs (Maksymowych et al., 1998, Maksymowych et al., 
2004, Ahsan et al., 2005, Couesnon et al., 2008). Previous work also suggests that BoNT/B is 
able to use a similar transport (Maksymowych et al., 1998). To investigate whether HCcB 
enters the mouse intestinal mucosa in in vivo conditions through a similar transcytotic 
mechanism, Dynasore, a specific inhibitor of endocytosis which blocks dynamin function 
(Harper et al., 2013), was injected (10 µg) into an ileal loop of anesthetized mice 20 min prior 
the injection of fluorescent HCcB. Mice were then sacrificed 10 min after the administration 
of fluorescent HCcB. As controls, we checked that administration of Dynasore and/or HCcB 
did not induced morphological alteration of the intestinal mucosa as monitored by E-cadherin 
staining of intestinal epithelial cells (Fig. 2A and B). In ileal loops, which only received 
fluorescent HCcB, an intense intracellular staining of rare intestinal epithelial cells and 
staining of filamentous elements in the mucosa and musculosa was observed (Fig. 2A). In 
contrast, in the ileal loops pretreated with Dynasore, fluorescent HCcB showed a different 
staining pattern. Thus, HCcB staining was mostly observed on the surface of intestinal villi 
and in the inter-villi spaces, whereas only a few filamentous structures were labeled in the 
submucosa and musculoasa (Fig. 2B). No morphological alteration of the basolateral 
epithelial cell membranes was evidenced as monitored by E-cadherin immunostaining (Fig. 
2A and B, middle panels). Quantification of fluorescence intensity in the submucosa and 
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musculosa indicated that Dynasore impaired by almost 90% the transcytosis of fluorescent 
HCcB across the intestinal barrier (Fig. 2C). The significant Dynasore-induced inhibition of 
HCcB staining of target cells in the submucosa and musculosa strongly supports a transcytotic 
passage of HCcB through the intestinal epithelial barrier.  
 
Endocytosis-dependent entry of BoNT/B into the mouse intestinal mucosa 
 Experiments were performed with purified BoNT/B to further assess that the results 
obtained with HCcB were representative of the trafficking of the whole toxin. For this, ligated 
mouse intestinal loops were injected with purified BoNT/B (100 µg) and were then processed 
for imaging studies as described above. After 10 min administration, BoNT/B was detected 
with immunopurified polyclonal antibodies directed against the HCc domain. BoNT/B was 
visualized on the surface of some villi after 10 min toxin administration as shown in Fig. 3A 
(upper panel), and decorated filamentous structures in the villi, submucosa and musculosa. 
BoNT/B was mostly localized in the submucosa and musculosa after a 20 min incubation time 
period (Fig. 3A, lower panels). Thereby, a similar pattern of staining was observed between 
HCcB and purified BoNT/B.  
 Next, we checked whether BoNT/B like HCcB enters the intestinal mucosa through a 
transcytotic mechanism. Pretreatment of intestinal loop with Dynasore (10 µg) for 20 min 
significantly reduced the detection of BoNT/B in the submucosa and musculosa (Fig. 3C). No 
morphological alteration of the intestinal mucosa was observed in the intestinal loops treated 
with Dynasore and/or BoNT/B (not shown). Compared to intestinal loops treated with 
BoNT/B in the absence of Dynasore, only a few cells and filament structures were labeled in 
the submucosa and musculosa from Dynasore pretreated intestinal loops (Fig. 3C). Dynasore 
induced a 80% decrease in the BoNT/B staining in both submucosa and musculosa (Fig. 3D), 
further supporting that similarly to HCcB, BoNT/B uses a transcytotic pathway to pass 
through the intestinal epithelial barrier. In addition, these results support the view that HCcB 
and BoNT/B use a similar traffic pathway in the mouse intestinal mucosa. 
 
HCcB and BoNT/B target neuronal cells in mouse intestinal submucosa and musculosa 
 Imaging analyses with antibodies against neurofilaments (NF) were performed to 
identify the cells and filamentous structures recognized by fluorescent HCcB in the 
submucosa and musculosa. Fluorescent HCcB was localized on long cell extensions co-
labeled with anti-NF antibodies (Fig. 4A and B). However, not all but only certain cell 
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extensions were recognized by both HCcB and anti-NF antibodies (Fig. 4A and B). Partial 
colocalization between the two markers (Pearson coefficient 0.38 ± 0.06) suggested that 
HCcB did not bind directly to NF, but rather bound to cells and cell extensions containing NF.  
We took advantage of Thy1-yellow fluorescent protein (YFP) transgenic mouse in the 
C57BL6 genetic background, which have been widely used to analyze the morphology and 
function of neurons in the mouse brain (Feng et al., 2000, Vuksic et al., 2008), to visualize 
neurons of the enteric nervous system (ENS). Thy1-YFP is mainly expressed in the Golgi 
apparatus of certain subpopulations of neurons (Feng et al., 2000). In the intestinal submucosa 
and musculosa of Thy1-YFP mice, neuronal cells were discontinuously labeled, to some 
extent due to the accumulation of YFP around the nuclei (Fig. 5A). Some neuronal cells 
showed an intense YFP expression in the cytosol in cell bodies and extensions. Fluorescent 
HCcB injected into the intestinal lumen of Thy1-YFP mice co-stained YFP labeled cells and 
cell extensions after 10 min after injection (Fig. 5A). However, not all but only some 
subpopulations of YFP-expressing neurons were recognized by HCcB (Fig. 5A). The low 
Pearson coefficient (0.241 ± 0.11) between YFP and Cy3-HCcB, indicates that the two 
markers labelled distinct structures of the same cells.  
 Synaptotagmin (Syt) has been evidenced as the receptor protein part which in 
combination with gangliosides of the GD1b and GT1b series forms the high affinity receptor 
of BoNT/B. Indeed, BoNT/B binds to the intraluminal domain of synaptotagmin I (SytI) and 
(SytII) through the HCc domain (Nishiki et al., 1996, Dong et al., 2003, Rummel et al., 2007, 
Rummel, 2013). Antibodies against SytII labeled cells and cell extensions in mouse intestinal 
submucosa and musculosa which were co-labelled with YFP in Thy1-YFP mice (Fig. 5A). 
Similar results were obtained with anti-SytI antibodies (not shown). Fluorescent HCcB 
specifically recognized cells and cell extensions expressing both Thy1 and SytII (Fig. 5A). 
This supports that HCcB targeted specific neurons expressing SytII in mouse intestine. The 
low Pearson's coefficient (0.24 ± 0.11) between HCcB staining and YFP expression also 
indicates that HCcB did not colocalize with YFP molecules but recognized cells expressing 
YFP-Thy1. In contrast, the high level of colocalization between HCcB and SytII (Pearson's 
coefficient: 0.51 ± 0.11) supports that SytII is a specific BoNT/B receptor in intestinal 
neuronal cells. 
Glial cells are abundant in the nerve tissues as well as in the ENS where they show 
multiple extensions, mainly in the submucosal and myenteric plexus, and in close contact 
with neuronal cells (Yu et al., 2014). Glial cells from the mouse intestinal mucosa were 
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specifically visualized with antibodies against the glial fibrillary acidic protein (GFAP) (Fig. 
5B). Since glial cells, are wound around neuronal cells an apparent high Pearson's coefficient 
(0.35 ± 0.03) was observed between HCcB-Cy3 and GFAP stained cells (Fig. 5B). Indeed, 
glial cell extensions are in close contact with those of neuronal cells but they are shorter. 
HCcB labeling pattern of cell extensions correlated with that of NF staining but was distinct 
from that obtained with GFAP staining (Fig. 5B). These findings suggest that HCcB entered 
the intestinal mucosa and targeted specific neuronal cells and extensions in the submucosa 
and musculosa and did not interact with glial cells in the mouse intestine. 
 
HCcB targets cholinergic neurons in the mouse intestine 
 BoNTs are known to interact with cholinergic neurons and to block spontaneous and 
evoked quantal ACh release (Schiavo et al., 2000, Poulain et al., 2008, Rossetto et al., 2014). 
However, BoNTs are able to enter various neuronal cell types and to inhibit the release of a 
large range of other neurotransmitters such as ACh, glutamate, gamma-aminobutyric acid 
(GABA) (reviewed in (Dolly et al., 2009, Popoff et al., 2010).  
 First, imaging studies were carried out to test whether HCcB targets cholinergic 
neurons using antibodies directed again choline acetyltransferase (ChAT). Most of the ChAT 
immunoreactive neuronal cell extensions from the submucosa and musculosa were co-
labelled with HCcB (82.2 % ± 3.8) 10 min after its administration in the intestinal loop (Fig. 
6A, and Table 1). ChAT neuronal cells labeled with HCcB also contained SytII (Sup. Fig. 
1A). Similar results were obtained with whole BoNT/B injected into the intestinal lumen and 
detected with specific immunopurified antibodies (Fig. 7A). After 10 min incubation, a large 
proportion of ChAT immunoreactive neuronal cells of the submucosa and musculosa were co-
stained with anti BoNT/B antibodies (87% ± 2.5) (Fig. 7A). However, it is noteworthy that 
HCcB or BoNT/B also labelled other neuronal cell types than ChAT neuronal cells, but to a 
lower extent. 
 
Distinct neuronal cells recognized by HCcB in the mouse intestine 
Binding of BoNT/B to the diverse neuronal cell types in mouse intestine was 
investigated by colocalisation analysis of HCcB-Cy3 with specific neuronal cell markers. 
Only a low number of neuronal cells were stained with anti-serotonin (5-hydroxytryptamine, 
5-HT) antibodies in the submucosa and myenteric plexuses of the mouse intestine. After 10 
min administration of HCcB or BoNT/B into the ileum lumen, a significant proportion (25 – 
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35 %) of serotonin-immunoreactive cells was co-labeled with fluorescent HCcB or anti 
BoNT/B antibodies (Fig. 6B and 7B, and Table 1). It is noteworthy that the serotonin-
immunoreactive cells labeled with HCcB also expressed SytII (Sup. Fig. 1B). 
 The other neuronal cell types are underrepresented in ENS and were variably 
recognized by HCcB-Cy3. Indeed, a low proportion estimated to be about 10% of vasoactive 
intestinal peptide (VIP)-immunoreactive cells in the submucosa was co-stained with HCcB 
(Fig. 6C and Table 1). Furthermore, rare glutamate- and gamma-aminobutyric acid GABA-
immunoreactive cells stained with antibodies against vesicular glutamate (vGLUT) and 
GABA transporter (vGAT), respectively, were visualized in the intestinal submucosa and 
most of them were partially co-stained with fluorescent HCcB (Fig. 6D, 6E, and Table 1). 
 Interestingly, HCcB labeled filamentous structures inside the core of villi which were 
co-stained mostly with antibodies against ChAT (52.5 ± 2.9%) and to a lower extent with VIP 
antibodies (5 ± 2.5%) (Fig. 8). No serotonin-immunoreactive neuronal extensions were 
visualized in the intestinal villi. These structures recognized by HCcB are likely projections of 
intrinsic afferent neurons whose cell bodies are localized in the submucosa and which are 
mainly ChAT- and to a lower extent VIP-immunoreactive neurons (Furness et al., 2004). 
  
 
Intestinal cells involved in the passage of BoNT/B 
 Subsequently to administration of fluorescent HCcB in the intestinal lumen, certain 
cells of villous epithelium were intensely fluorescent. Albeit HCcB was observed inside the 
lumen of most intestinal crypts, no crypt cells retained HCcB fluorescence (Fig. 1). Similar 
findings were observed with BoNT/B injected into the intestinal lumen and detected with 
anti-HCcB antibodies (Fig. 2, Fig. 3C and D). The question arises as to whether the rare cells 
from the villous intestinal epithelium accumulating HCcB fluorescence reflect the 
transcellular translocation of HCcB and BoNT/B, or alternatively represent a site of toxin 
storage. Because these cells were mostly located in the upper part of intestinal villi, we first 
investigated whether they undergo apoptosis and thereby might non-specifically accumulate 
HCcB or BoNT/B. As shown in Sup. Fig. 2, no co-staining between fluorescent HCcB and 
activated Caspase3 antibodies was evidenced indicating that the fluorescent HCcB stained 
cells were not apoptotic.  
The inhibitory effect of Dynasore on the transport of HCcB or BoNT/B across the 
intestinal epithelium (Fig. 2 and 3B) suggests an apical endocytic uptake and subsequent 
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transcytotic delivery of HCcB or BoNT/B through the basolateral side. Colchicine, which is a 
tubulin filament disruption agent, impairs transcytosis in epithelial cells such as CaCo-2 cells 
(Bose et al., 2007), and has been used to inhibit the translocation of Listeria monocytogenes 
across the intestinal epithelium in an intestinal ligated loop model (Nikitas et al., 2011). 
Pretreatment of mouse intestinal loops with colchicine in the same conditions than for the L. 
monocytogenes experiments (10 µg/ml, 20 min) (Nikitas et al., 2011) prior to the injection of 
fluorescent HCcB, induced a significant increased number of villous epithelial cells 
accumulating HCcB (Fig. 9A and 9B). In addition, the HCcB fluorescence in intestinal loops 
pretreated with colchicine was mainly localized at the periphery of the epithelial cells which 
accumulated HCcB, whereas in the non-pretreated intestinal loops the epithelial cells which 
retained HCcB were uniformly stained, possibly resulting from a different traffic pathway 
than in colchicine-treated cells (Figs. 9A and 9B).  However, colchicine pretreatment did not 
significantly prevent HCcB staining of neuronal cells in the submucosa and musculosa (Fig. 
10), indicating a delayed passage of HCcB through certain villous cells, independently of the 
one inhibited by colchicine.  
The cells which accumulated fluorescent HCcB, were not stained with phalloidin, a 
marker of actin filaments (Fig. 9A). This finding strongly suggests that HCcB accumulated in 
a subset of intestinal cells devoid of apical brush border, and raises the question whether 
BoNT/B uses specific cells for its transport through the intestinal barrier? To address this 
question, we investigated whether the HCcB labeled cells belong to a specific sub-population 
of the intestinal epithelium, using various markers of already characterized cell subsets of the 
intestinal epithelium: wheat germ agglutinin (WGA) which binds specifically to sialic acid 
and N-acetylglucosaminyl carbohydrate residues in mucous of goblet cells (Jang et al., 2004), 
Lectin Urex europeus agglutinin type 1 (UEA1) which recognizes Paneth cells (Garabedian et 
al., 1997), antibodies anti-CD3 and anti-CD11C two markers of lymphocytes and dendritic 
cells, respectively, which are localized in the intestinal lamina propria (Montufar-Solis et al., 
2007, Persson et al., 2013), anti-villous M cells shown to be the principal site of gut luminal 
antigen uptake (Jang et al., 2004), chromogranin A which represents a common marker of 
enteroendocrine cells (Portela-Gomes et al., 2000), and the double cortin kinase 1 protein 
(DCLK1) specific of tuft cells, a class of secretory intestinal cells distinct from 
enteroendocrine  cells, Paneth, cells and goblet cells (Gerbe et al., 2011). Additional markers 
of goblet cells were used like antibodies specific of the intestinal trefoil factor (ITF) or 
cytokeratin18 (Poulsom et al., 1993, Hesse et al., 2007). Double immunofluorescence studies 
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using the various cell-specific antibodies or markers and fluorescent HCcB clearly showed 
that none of the markers tested colocalized or co-stained with HCcB labelled cells in the 
intestinal epithelium (Sup. Fig. 3 and 4). Furthermore, the rare cells of the villous epithelium 
exhibiting ChAT immunoreactivity were not targeted by HCcB (Sup. Fig. 3).  
Transcytosis through intestinal cells indicates that HCcB or BoNT/B recognizes 
specific cell surface receptor(s). Are BoNT/B receptors on intestinal cells the same than those 
on neuronal cells (gangliosides of the GD1b/GT1b series in combination with SytII)? An 
excess of GT1b has been found to prevent BoNT/B binding to synaptosomes (Atassi et al., 
2014). A competition experiment was performed between HCcB and GT1b for binding and 
entry of toxin into the intestinal mucosa. As shown in Fig. 11, in contrast to control intestinal 
loop treated with only labeled HCcB, preincubation of HCcB with GT1b significantly 
prevented HCcB staining of intestinal villi, submucosa and musculosa. Only a faint HCcB 
staining was observed in certain villi, whereas no staining was visualized in the submucosa 
and musculosa. As control, GM1 was found to not impair HCcB entry into the intestinal 
mucosa (Sup. Fig. 5). Moreover, no labeling of intestinal epithelial cells with anti-SytII 
antibodies was evidenced, suggesting that BoNT/B uses GT1b but a distinct protein receptor 
from that of neuronal cells to enter intestinal cells. 
 
 
DISCUSSION 
 Translocation of BoNT through the intestinal barrier is a critical initial step in 
botulism resulting from the ingestion of toxin preformed in food or from intestinal 
colonization by C. botulinum. In in vitro cultures, food or intestinal content, BoNT is 
produced in complex forms by non-covalent association with ANTPs. Whether whole 
botulinum complexes or only BoNT pass through the intestinal barrier and the mode of its 
transport remain under debate. ANTPs play an essential role in the protection of BoNT 
against the stomach acidic pH and digestive proteases. The non-toxic non-hemagglutinin 
(NTNH) component of C. botulinum type A, is structurally related to BoNT/A and associates 
with BoNT/A in a pH-dependent manner to form a medium size botulinum complex highly 
resistant to acidic pH and protease degradation (Gu et al., 2012, Gu et al., 2013). It is 
noteworthy that NTNH is synthesized by all C. botulinum types and likely retains the same 
function in the various corresponding botulinum complexes. HAs, which are found in various 
BoNT complexe types, have been evidenced to mediate the absorption of botulinum complex 
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from the gut. HAs interact with oligosaccharides on the intestinal epithelial cells and possibly 
facilitate the toxin uptake into intestinal cells (reviewed in (Fujinaga et al., 2013, Gu et al., 
2013)). The HA-mediated transport of BoNT/A complex through the intestinal barrier seems 
to preferentially occur via microfold (M) cells (Matsumura et al., 2015). In addition, HAs 
bind to and disrupt E-cadherin-mediated intercellular junctions, thus allowing the passage of 
BoNT through the intestinal barrier via the paracellular route (reviewed in (Fujinaga et al., 
2013, Gu et al., 2013). However, HAs are not produced by C. botulinum E, F and certain type 
A strains which are also involved in human botulism by the oral route (Simpson, 2013, Singh 
et al., 2014). These C. botulinum strains form BoNT complexes containing OrfX proteins 
instead of HAs (Hill et al., 2013, Popoff et al., 2013). However, OrfX proteins have not been 
found to interact with intestinal cells indicating that BoNT can itself cross the intestinal 
barrier without the help of additional protein. Therefore, when administrated into the small 
intestine, BoNT free of HAs and BoNT complexes are absorbed through the intestinal barrier 
in an equally efficient manner (Maksymowych et al., 1999). Moreover, purified BoNT was 
demonstrated to bind to intestinal cells, and to undergo receptor-mediated endocytosis, 
transcytosis, and subsequent release from the baso-lateral side (Maksymowych et al., 1998, 
Maksymowych et al., 2004, Ahsan et al., 2005, Couesnon et al., 2009). Here, we investigated 
the entry of BoNT/B into the intestinal mucosa in an in vivo mouse model using purified 
BoNT/B or the recombinant HCcB fragment. The corresponding C-terminal domain of 
BoNT/A has already been used to monitor the holotoxin trafficking in cultured cells or intact 
intestinal mucosa (Maksymowych et al., 2004, Ahsan et al., 2005, Couesnon et al., 2012). 
 When administrated into a mouse jejuno-ileal ligated loop, a progressive passage of 
the fluorescent HCcB or BoNT/B from the intestinal epithelium to the submucosa and 
musculosa was visualized. Within 10-20 min, HCcB or BoNT/B targeted neuronal structures 
in the submucosa and musculosa. This rapid passage contrasts with the longer time (30-60 
min) observed for the internalization of HCcA in the mouse intestinal mucosa (Couesnon et 
al., 2012). However, the experimental conditions used for HCcA investigation were slightly 
different. Mouse intestinal loops were excised, transferred into oxygenated culture medium, 
and incubated at room temperature after intraluminally injection of HCcA (Couesnon et al., 
2012). In the present work, the vascularization of the intestinal loops and the physiological 
mouse temperature were maintained. Thereby, in the more physiological conditions, a more 
rapid trafficking was observed indicating that BoNT/B translocation into the mouse intestinal 
mucosa is a rapid process. However, the difference in the experimental procedures does not 
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fully exclude that BoNT types A and B may have a different way and kinetics of entry into 
the intestinal mucosa.  
 Interestingly, Dynasore which is an inhibitor of dynamin-dependent endocytosis 
process (Macia et al., 2006, Harper et al., 2013), significantly prevented the entry of HCcB or 
BoNT/B into the mouse intestinal mucosa (Fig. 2 and 3). The in vivo mouse model of ligated 
intestinal loop clearly supports that BoNT/B free of HAs or the receptor binding domain, 
HCcB, were able to pass through the intestinal barrier via an endocytic mechanism to target 
specific cells in the intestinal submucosa and musculosa. It should be noticed that the toxin 
amounts used in this study were higher than those expected in natural acquired botulism. 
Minimum amounts of fluorescent HCcB yielding detectable signal in intestinal tissues were 
around 10 µg per intestinal loop (Sup Fig. 6). We selected to use higher amounts (100 
µg/intestinal loop) to more efficiently visualize the cells mediating toxin trafficking. Since 
high HCcB or BoNT/B doses were efficiently inhibited by endocytosis inhibitor (Fig. 2 and 3) 
or in competition experiments with specific receptor such as GT1b (Fig. 10), and since only a 
restricted number of cell types were visualized (Fig. 1 and 3), the physiological toxin 
trafficking was likely preserved in these experimental conditions. Although lower amounts of 
HCcA (0.5 µg/ intestinal loop) (Couesnon et al., 2012) or BoNT/A (0.6 µg orally per mouse) 
(Lam et al., 2015) were used. However we were unable to reproduce the results with 0.6 µg 
BoNT/A per mouse. Moreover, it has to be taken in account that BoNT/B is less active than 
BoNT/A, about 10-fold less (Foran et al., 2003, Rasetti-Escargueil et al., 2009), and that only 
a low toxin fraction passes through the intestinal barrier based on in vivo experiments 
(reviewed in (Popoff et al., 2014)) therefore justifying the amounts used in this study. 
However, one cannot fully exclude that in the present work, HCcB or BoNT/B uses different 
entry pathways than in the in vivo situation.  
 HCcB or BoNT/B enters the mouse intestinal mucosa and specifically targets neuronal 
cell bodies and neuronal cell extensions in the submucosa and musculosa as visualized by co-
staining of the filamentous structures with anti-NF antibodies and HCcB or BoNT/B (Fig. 4). 
Glial cells which are abundant in the intestinal mucosa were not recognized by HCcB (Fig. 5). 
These observations were further supported by the use of the transgenic Thy1-YFP mouse 
which exhibits a nice labeling of the ENS, and co-staining of neuronal filaments expressing 
Thy1-YFP with HCcB (Fig. 5). It is noteworthy that HCcB or BoNT/B only recognizes 
certain neuronal cell extensions. Neuronal cell filaments identified by anti-NF antibodies or 
by Thy1-YFP expression were not all co-stained with HCcB (Fig. 5). Interestingly, HCcB and 
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BoNT/B colocalized with SytII antibodies on intestinal neuronal extensions (Fig. 5 and Sup 
Fig. 1) in agreement with previous characterization of SytII as the BoNT/B receptor (Nishiki 
et al., 1996, Dong et al., 2003, Chai et al., 2006). ChAT and serotonine neurons labeled with 
HCcB also expressed SytII (Sup. Fig. 1), and likely the other neuronal cell types targeted by 
BoNT/B. Collectively the present findings support that BoNT/B uses SytII as specific 
receptor on neuronal cell extensions of the ENS. 
 Neuronal cells of the ENS are organized in the submucosa and myenteric plexuses, 
which project on the different layers of the intestinal mucosa. ENS neurons can synthesize a 
wide variety of neurotransmitters. More than 20 types of neurotransmitters have been 
identified in ENS and most enteric neurons may produce and secrete several of them (Goyal 
et al., 1996, Grundy et al., 2006, Furness, 2012). Cholinergic neurons are the greater 
population of enteric neurons. In the submucosal plexus, cholinergic neurons (about 55% of 
the enteric neurons) regulate ion secretion and are involved in local sensory pathways in 
response to the luminal content composition. In addition, they interact with Peyer's patch 
follicles (Kulkarni-Narta et al., 1999, Furness et al., 2004, Harrington et al., 2010). 
Cholinergic neurons are preponderant in the myenteric plexus (about 80%) and have a main 
function in mediating muscle activity and controlling intestinal motility (Furness et al., 2004, 
Harrington et al., 2010). Serotonin is a major mediator of gastrointestinal function. Notably 
serotonin controls motility, secretion, and sensory responses. Serotonin is mainly produced by 
enteroendocrine cells from the mucosal epithelium of the intestine and 2 to 20% of enteric 
neurons are serotonin immunoreactive (McLean et al., 2007, Mawe et al., 2013). VIP-
immunoreactive neurons are the most preponderant non-cholinergic neurons of the ENS and 
constitute the main class of inhibitory interneurons. VIP-immunoreactive neurons are 
estimated to represent about 45% of neurons of the submucosal plexus in the ileum and 
jejunum. VIP modulates several functions including vasodilatation of intestinal vessels, 
intestinal smooth muscle relaxation, and stimulation of electrolyte secretion and water 
(Brookes, 2001, Furness et al., 2004, Hernandes et al., 2004, Igarashi et al., 2011, Furness, 
2012). Glutamate and GABA are neurotransmitters produced by a few number of ENS 
neuronal cells (Furness, 2000, Furness et al., 2004). 
 In in vivo experiments HCcB or BoNT/B targeted certain but not all neuronal cells at 
the Syt binding sites. Cholinergic neurons of ENS were the main target of HCcB or BoNT/B, 
since more than 80% of the ChAT immunoreactive neuronal cells were co-stained with HCcB 
or BoNT/B (Table 1). This is in agreement with the fact that BoNT/B like the other BoNT 
types, mainly target peripheral cholinergic motor neuron endings (Simpson, 2013, Rossetto et 
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al., 2014). HCcA was also found to preferentially localize to cholinergic neurons of the 
submucosa and musculosa of the mouse intestine (Black et al., 1987, Couesnon et al., 2012). 
HCcB also targeted cholinergic extensions in the villi and around the intestinal crypts. 
Constipation is a frequent symptom (about 70%) in food-borne botulism and is a major and 
early event in botulism resulting from intestinal colonization (Arnon et al., 2001, Sobel, 2005, 
Brook, 2007, Mitchell et al., 2008). Since cholinergic neurons are the main players of the 
control of intestinal motility and secretion (Furness, 2012), ChAT-immunoreactive targeting 
by BoNT likely account for the reduced intestinal peristalsis and secretion observed in 
botulism. During botulism by intestinal colonization, BoNT produced in the intestinal lumen 
might be absorbed in a higher local concentration able to enter the intestinal mucosa and 
inhibit the underlying cholinergic neurons compared to orally ingested toxin which 
disseminates more broadly through the digestive tract. 
 HCcB or BoNT/B targeted other neuronal cell types than cholinergic neurons in the 
mouse intestinal mucosa but to a lower extent. Serotonin-immunoreactive neuronal cells were 
significantly co-stained with HCcB or BoNT/B (25 to 35%) (Table 1), whereas a lower 
proportion (about 10%) (Table 1) of VIP-immunoreactive neurons was stained with HCcB. In 
the present work, only rare V-GLUT- and V-GAT-immunoreactive cells were visualized in 
the intestinal mucosa and most of them co-stained with HCcB. However, the low number of 
identified cells did not allow estimating precisely the proportion of these sub-cell types 
targeted by HCcB.  
The pathophysiological effects of BoNT on the non-cholinergic neurons are still a 
matter of debate. Serotonin is an important neurotransmitter in the gastrointestinal tract which 
is involved in multiple functions including intestinal motility and secretion. Although most 
part of serotonin is secreted by enteroendocrine cells, serotoninergic neurons have an essential 
role in the gastrointestinal motility (Li et al., 2011, Gershon, 2013). BoNT/B effects on 
serotoninergic neurons of the intestinal mucosa might contribute to the inhibition of intestinal 
motility in synergy with the blockade of ACh release at cholinergic nerve endings. The 
incidence of BoNT/B on the small part of VIP-immunoreactive neurons targeted by HCcB, 
remains speculative. Since one of the main roles of VIP is to control gastrointestinal secretion 
(Igarashi et al., 2011, Furness et al., 2014), BoNT/B may exert its anti-secretory effect 
partially through inhibition of VIP release. BoNT/B might use non-cholinergic neurons not 
only to contribute to the local paralytic effects, but also to disseminate to other target neurons 
locally or at distance from the intestine. Indeed, BoNT/A has been shown to use a retrograde 
transport and transcytosis to migrate from the peripheral neurons to the central nervous 
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system (Antonucci et al., 2008, Restani et al., 2011, Restani et al., 2012). Since the neurons 
of ENS are highly interconnected between them and with neurons of the central nervous 
system (Goyal et al., 1996, Grundy et al., 2006, Furness et al., 2014), one can speculates that 
BoNT/B uses non-cholinergic intestinal neurons for its transport to remote target neurons. 
 The present findings also raises an intriguing question: does BoNT/B use preferential 
cells to cross the intestinal barrier? In contrast to BoNT/A, which has been found to enter the 
intestinal mucosa preferentially via crypt enteroendocrine cells (Couesnon et al., 2012), no 
HCcB or BoNT/B labeling was detected in epithelial crypt cells, or enteroendocrine cells 
using anti-chromogranin A antibodies. Accumulation of HCcB or BoNT/B was observed in a 
few villous epithelial cells lacking apical actin staining (e.g. devoid of apical brush border). 
The fact that cells accumulating HCcB were not apoptotic cells rule out the possibility of non-
specifically fluorescent protein accumulation. Using a wide panel of markers of intestinal 
epithelial and lymphocytic cells, the villous cells labeled with HCcB or BoNT/B could not be 
assigned to any already known subset of cell type. Whether these cells represent the toxin 
passage through the intestinal barrier remains questionable? A transcytotic passage supposes a 
continuous trans-cellular toxin passage over time. However, a transient accumulation in some 
intracellular compartment is not fully excluded. Time lapse monitoring the passage of 
fluorescent HCcB could be more informative. The in vivo experiments used in this study 
allowed collection of intestinal samples only at different time points. Pretreatment with 
colchicine, an inhibitor of microtubule-dependent transcytosis, evidenced an increased 
number of villous epithelial cells accumulating HCcB, but with a distinct pattern of 
fluorescent labeling than in colchicine-untreated intestinal loops (Fig. 9). HCcB was mainly 
observed on the basolateral peripheries of epithelial cells from pretreated intestinal loops with 
colchicine, whereas HCcB accumulated broadly into the intracellular space in non-pretreated 
loops. However, colchicine did not prevent significantly the HCcB passage to the underlying 
neuronal cells. Thus, it cannot be excluded that colchicine delayed, but not completely 
blocked, the transcytotic passage of HcCB in these subsets of villous cells. The absorption of 
BoNT from the digestive tract is a very low efficient process. In vivo experiments showed that 
less than 0.01 to 0.1% of intraduodenally administrated BoNT can be recovered in lymph of 
blood circulation (reviewed in (Popoff et al., 2014)). Thus, a low toxin passage through the 
enterocytes or at least some of them may support the weak intestinal absorption of toxin 
which has been observed in vivo. 
 In conclusion, the present study using an in vivo model of mouse ligated intestinal 
loop demonstrates that HCcB or BoNT/B free of HAs can pass through the intestinal barrier 
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via an endocytosis-dependent mechanism since Dynasore, a specific inhibitor of endocytosis, 
significantly prevented their translocation. After 10-20 min incubation time, HCcB or 
BoNT/B specifically targeted neuronal cells and neuronal extensions in the submucosa and 
musculosa. Binding of HCcB or BoNT/B to neurons correlated with Syt expression, in 
agreement with the identification of Syt as the specific BoNT/B receptor (Nishiki et al., 1996, 
Dong et al., 2003, Rummel et al., 2007, Rummel, 2013). Cholinergic intestinal neurons were 
the main targets of HCcB or BoNT/B together with other neuronal cell types of the intestinal 
mucosa, notably serotoninergic neurons and to a lower extent VIP, V-GLUT and V-GAT-
immunoreactive neurons. Although HCcB or BoNT/B accumulated in some intestinal cells, 
those which mediate the passage of BoNT/B remain to be identified. 
 
EXPERIMENTAL PROCEDURES 
Ethic statements 
All experiments were performed in accordance with French and European Community 
guidelines for laboratory animal handling. The protocols of experiments were approved by 
Pasteur Institute CETEA (Comité d'Ethique en Expérimentation Animale) with the agreement 
of laboratory animal use (n° 2013-0118). 
 
Animals 
Adult Swiss mice (Charles River) and Thy-1 yellow fluorescent protein protein (YFP) 
transgenic mice (C57BL6 backgroung, Jackson Research) were used.  
 
Reagents  
Tissues were stained with Hoechst (Dako, 1:1000 dilution) for the nuclei, FITC- 
phalloidin (Sigma, 0.4mg/ml), FITC-Urex europaeus agglutinin type 1 (UEA1) (Sigma, 1 
mg/ml), wheat germ agglutinin alexa fluor 488 conjugate (Invitrogen, 1:500 dilution). The 
primary antibodies used recognized E-cadherin (Invitrogen, rat, 1:250 dilution), neurofilament 
(Sigma, rabbit, 1:250 dilution), Choline Acetyltransferase (ChAT) (Millipore, goat, 1:100 
dilution), serotonin (Abcam, goat, 1:1000 dilution), chromogranin A (Abcam; rabbit, diluted 
1:250), synaptotagmin II (SytII) (Abcam, rabbit, 1:250 dilution), Glial Fibrillary Acidic 
Protein (GFAP) (Sigma; rabbit, 1:200 dilution), VIP (Abcam; rabbit, diluted 1:200), vesicular 
glutamate transporter 1, BNPI, SLC17A7 (VGLUT 1) (Synaptic System, rabbit, 1:250 
dilution), vesicular GABA transporter (VGAT) (Synaptic System, rabbit, 1:250 dilution), 
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activated caspase-3 (Cell Signaling 9661, rabbit, 1:200), DCLK1 (Abcam, rabbit, 1:200 
dilution), M cell villi (MACS Miltenyi Biotec, rat, 1:200 dilution), Anti CD11c clone HL3 
(BD Bioscience, armenian hamster, 1:250 dilution), integrin aE (CD3) (BD Pharmingen, 
syrian hamster, 1:200 dilution), cytokeratin 18 (Abcam, biotinylated mouse monoclonal 
antibody, 1:100 dilution), intestinal trefoil peptide (Santa Cruz, rat, 1:100 dilution). The 
secondary antibodies were Alexa fluor 488 or 647 donkey anti goat, alexa fluor 488 or 647 
goat anti rat, Alexa fluor 488 donkey anti rabbit, Alexa fluor 594 goat anti rabbit (Invitrogen, 
1:500 dilution), Alexa fluor 647 anti Syrian hamster (Jackson Immunoresearch, 1/500 
dilution), Alexa fluor 647 goat anti Armenian hamster (Jackson Immunoresearch, 1/500 
dilution). Endocytosis assay were perform with Dynasore Hydrate (Sigma, 10 µg/intestinal 
loop). Other reagents: Colchicine (Sigma, 10 µg/ml), trisialoganglioside GT1b (Sigma 
G3767), ganglioside GM1 (Sigma 345724).   
 
Botulinum neurotoxin and recombinant HCcB protein production 
BoNT/B was produced and purified as previously described (Shone et al., 1995). 
Recombinant His-tag HCc fragment of BoNT/B was produced and purified from pET-28a-
c(+) vector containing DNA encoding for HCcB cloned into BamHI and SalI sites, as 
previously described (Tavallaie et al., 2004). HCcB His-tag was labeled with Amersham Cy3 
Mono-Reactive Dye Pack (Ge Healthcare) according to the manufacturer’s recommendations. 
Free dye is removed from labelled protein using the de Zeba Spin Desalting Columns 
according to the manufacturer’s recommendations (Thermo Scientific).  
 
In vivo intestinal ligated loop experiment  
Swiss mice (between 20 and 22 g) or Thy-1 YFP transgenic mice were fasted for 16 h 
before surgery. Mice were deeply anesthetized with a mixture of ketamine (50 mg/kg body 
weight; Imalgene 1000; Merial) and medetomidine (0.5 mg/kg body weight; Domitor; Orion 
Corporation). A mouse laparotomy was performed and a jejuno-ileal loop (approximately 
4cm long) was isolated. Three hundred µl of labeled HCcB or purified BoNT/B containing 
100 µg protein were injected into the intestinal lumen. After incubation times (5 to 20 min) 
mice were euthanatized, the intestinal loops were harvested, opened longitudinally, washed 
repeatedly in 37°C Dulbecco’s modified Eagle’s medium (Invitrogen), and fixed flat (luminal 
side up) for 2 h in 4% paraformaldehyde (PFA) at room temperature.  
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In competition assay, Cy3-HCcB (70 µg) was preincubated with a 10-fold excess of 
ganglioside GT1b from bovine brain (Sigma G3767) for 20 min at room temperature and the 
mixture was injected into an intestinal loop. After 15 min incubation, the intestinal loops were 
processed for fluorescence microscopy. 
 
Intestinal tissue preparations and indirect immunofluorescence 
Fixed intestinal loops were embedded in 4% agarose and sections (150 µm) were cut 
with a vibratome (Polyscience – Bangs Laboratories). Sections were permeabilized with 0.4% 
triton X-100 for 1 h at room temperature, washed in PBS, and then incubated for 1 h in PBS-
BSA (3 %). Samples were then incubated or not with specific antibodies for 2 h at room 
temperature for primary antibodies and 1 h at room temperature for secondary antibodies in 
PBS-BSA (0.5 %) - Triton (0.2%). After 3 washes in PBS, sections were mounted in 
Fluoromount (FluorProbes) and samples were imaged using a Zeiss LSM700 confocal laser 
scanning microscope.  
 
Image analysis and statistics 
Image analysis was performed using ImageJ (National Institutes of Health). 
Colocalization test were performed using JacOp plugin from ImageJ. Values throughout the 
text are expressed as means ± standard deviations (SD). Differences were assessed using 
unpaired Student’s t-test. Statistical significance was assumed for P < 0.0001 (***) on at least 
3 independent experiments for integrated density measurements and a 100 counted cells for 
the percentage of co-labeled structures.  
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LEGENDS TO FIGURES 
 
Figure 1. Visualization of fluorescent HCcB in the mouse intestine following its injection 
into the intestinal lumen. HCcB-Cy3 (100 µg) in Dulbecco’s modified Eagle’s medium was 
injected into ligated jejuno-ileal loop of anesthetized mice. The intestinal loop was then 
introduced again into the mouse abdomen. After 5 (A), 10 (B), and 20 min (C), the intestinal 
loop was washed, fixed, sliced, and prepared for fluorescent confocal microscopy. The 
preparations were co-stained with Hoechst (blue) to visualize nuclei. (A) At 5 min incubation, 
HCcB was visualized (red labeling) on the surface and/or inside some villous epithelial cells, 
as well as in the inter-villous spaces. No or weak HCcB labeling was observed in the 
submucosa. (B) HCcB was observed inside intestinal crypts, in a few villous epithelial cells, 
and in filamentous structures in the villi and around intestinal crypts. HCcB markedly stained 
filamentous structures in the submucosa and musculosa. (C) At 20 min the HCcB staining of 
filamentous structures in the submucosa and musculosa was prominent. Scale bars = 10 µm. 
(D) Quantification of HCcB fluorescence in the villi and submucose/musculosa of intestinal 
loops. Values are mean ± SD from 3 independent experiments (3 to 5 quantifications in each 
experiment). ***P < 0.001. 
 
Figure 2. Inhibition of HCcB entry into the intestinal mucosa by Dynasore. HCcB-Cy3 
(100 µg) was injected into a control ligated jejuno-ileal loop (A) or into a ligated intestinal 
loop pretreated with Dynasore (10 µg, 20 min) (B). After 10 min HCcB incubation, the 
intestinal segments were prepared as described in Fig. 1. The HCcB staining (red) of 
filamentous structures in the submucosa and musculosa (A) was prevented by pretreatment 
with Dynasore (B). E-cadherin staining (A and B middle panels, white) showed no 
morphological alteration of the intestinal epithelium. The preparations were co-stained with 
Hoechst (blue) and ECDD2 (white). (C) Quantification of HCcB fluorescence in the 
submucosa and musculosa of intestinal loops pretreated or not with Dynasore and injected 
intraluminally with fluorescent HCcB. Fluorescence from intestinal loops treated with HCcB 
only was set to 100%. Values are mean ± SD from 3 independent experiments (3 to 5 
quantifications in each experiment).. Scale bars = 10 µm. ***P < 0.001 
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Figure 3. BoNT/B enters the mouse intestinal mucosa and its entry is prevented by 
Dynasore. BoNT/B (100 µg) was injected into ligated jejuno-ileal loop of anesthetized mice. 
After the indicated times, the intestinal segments were prepared as described in Fig. 1 and 
BoNT/B was detected with rabbit immunopurified immunoglobulins against HCcB and 
Alexa594-anti-rabbit immunoglobulins. (A) After 10 min incubation, BoNT/B was visualized 
in a few villous epithelial cells, as well as in filament structures inside the villi and to a lower 
extent in the submucosa. (B) At 20 min incubation, a marked BoNT/B staining of filamentous 
structures in the submucosa and musculaosa was evidenced. Epithelium brush border was 
visualized by actin staining with phalloidin (green) and nuclei with Hoechst (blue). (C) 
Pretreatment with Dynasore (10 µg, 20 min) followed by 10 min incubation with BoNT/B 
significantly prevented BoNT/B staining in the submucosa and musculosa. (D) Quantification 
of BoNT/B fluorescence in the submucosa and musculosa of intestinal loops pretreated or not 
with Dynasore and injected intraluminally with BoNT/B. Data are mean values ± SD, from 3 
independent experiments (3 to 5 quantifications in each experiment).. Scale bars = 10 µm. *** 
P < 0.001. 
 
Figure 4. HCcB stains neuronal cell extensions in mouse submucosa and musculosa. 
HCcB-Cy3 (100 µg) was injected into ligated jejuno-ileal loop and after 10 min incubation 
the intestinal samples were prepared as described in Fig. 1. Neuronal cell extensions were 
labeled with anti neuro-filament (NF) antibodies, and nuclei with Hoechst (blue). Scale bars = 
20 µm and 10 µm for the magnification panels. 
 
Figure 5. HCcB recognizes neuronal cell extensions expressing synaptotagmin II but not 
glial cells in mouse intestinal submucosa and musculosa. A, HCcB-Cy3 (100 µg) was 
injected into ligated jejuno-ileal loop of transgenic Thy1-YFP mice. After 10 min incubation 
the intestinal samples were prepared as described in Fig. 1. A, HCcB stained neuronal cells 
and cell extensions expressing Thy1-YFP (green) and co-stained with anti-synpatotagmin II 
antibodies (white). B, No co-staining of glial cells monitored with anti-GFAP antibodies and 
fluorescent HCcB was evidenced. Nuclei were stained with Hoechst (blue). Scale bars = 20 
µm and 10 µm for magnification panels.  
 
Figure 6. Neuronal cells specifically targeted by HCcB in mouse intestinal submucosa 
and musculosa.  HCcB-Cy3 (100 µg) was injected into ligated jejuno-ileal loop and after 10 
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min incubation the intestinal samples were prepared as described in Fig. 1. The preparations 
were co-stained with anti-ChAT (marker of cholinergic neurons), anti-serotonin, anti-VIP, 
anti V-GLUT (marker of glutamatergic neurons), anti-V-GAT (marker of GABAergic 
neurons) (green). Enlarged views of the drawn squares are shown on the right side. Hoechst 
(blue), ECCD2 (white). Scale bars = 20 µm and 10 µm for magnification panels. 
 
Figure 7. BoNT/B targeted cholinergic and serotonin neurons in the intestinal 
submucosa and musculosa. BoNT/B (100 µg) was injected into mouse ligated jejuno-ileal 
loop and after 10 min incubation the intestinal samples were prepared as described in Fig. 1. 
BoNT/B was detected with rabbit immunopurified immunoglobulins against HCcB and 
Alexa594-anti-rabbit immunoglobulins. The preparations were co-stained with anti-ChAT (A) 
and anti-serotonin (B). Enlarged views of the drawn squares are shown on the right side. 
Hoechst (blue). Scale bars = 20 µm and 10 µm for magnification panels. 
 
Figure 8. HCcB targeted cholinergic and VIP neurons in intestinal villi. HCcB-Cy3 (100 
µg) was injected into ligated jejuno-ileal loop and after 10 min incubation the intestinal 
samples were prepared as described in Fig. 1. Preparations were co-stained with antibodies 
anti-ChAT (cholinergic cells) or anti-VIP (green), and anti E cadherin (ECCD2) (white) and 
Hoechst (blue). Scale bars =20 µm and 10 µm in the magnification panels. 
 
Figure 9. HCcB accumulation in some cells of the intestinal epithelium. HCcB-Cy3 (100 
µg) was injected into ligated jejuno-ileal loop and after 10 min incubation the intestinal 
samples were prepared as described in Fig. 1. (A) HCcB accumulated in a few cells of the 
intestinal epithelium which showed no apical actin staining. (B) Colchicine pretreatment (10 
µg/ml, 30 min) increased the number of cells accumulating HCcB. HCcB is preferentially 
distributed on the apical or basolateral sides of the cells from colchicine pretreated intestinal 
loop (B), in contrast to a broad HCcB distribution through cells of untreated intestinal loops 
(A). Note that the cells accumulating HCcB in the intestinal epithelium did not show 
Phalloidin staining of their apical side. Hoechst (blue). Scale bar = 10 µm. 
 
Figure 10. Colchicine does not totally block the intestinal passage of HCcB-Cy3. HCcB-
Cy3 (100 µg) was injected into ligated jejuno-ileal loop with or without pretreatment with 
colchicine (10 µg/ml, 30 min). Albeit colchicine induced HCcB-Cy3 accumulation into 
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certain intestinal epithelial cells, it did not completely impaired HCcB-Cy3 dissemination to 
neuronal cells in the submucosa and musculosa. Hoechst (blue). Scale bar = 10 µm. 
 
Figure 11. HCcB uses ganglioside GT1b as receptor on intestinal cells. HCcB-Cy3 (70 
µg) was injected into ligated jejuno-ileal loop (A) or incubated with a 10-fold excess of GT1b 
for 20 min at room temperature prior to injection into intestinal loop (B). After 15 min 
incubation the intestinal samples were prepared as described in Fig. 1. Prior incubation with 
GT1b significantly prevented HCcB staining of intestinal villi, submucosa, and musculosa. 
(C) Quantification of HCcB staining of the intestinal wall. Scale bars = 20 µm. ***P < 0.001. 
(3 to 5 quantifications in each experiment). 
 
Supplementary Figure 1.  HCcB recognizes neuronal cell extensions expressing 
synaptotagmin II in mouse intestinal submucosa and musculosa. HCcB-Cy3 (100 µg) was 
injected into mouse ligated jejuno-ileal loop. After 10 min incubation the intestinal samples 
were prepared as described in Fig. 1. HCcB stained neuronal cells and cell extensions 
expressing serotonin (A) (green) or ChAT (B) (green) and co-stained with anti-
synpatotagmin1 (SytII) antibodies (white), and Hoechst (blue). Scale bars = 20 µm and 10 µm 
for magnification panels.  
 
Supplementary Figure 2. Cells of the intestinal epithelium which accumulated HCcB, were 
not immunoreactive with antibodies against caspase 3. HCcB-Cy3 (100 µg) was injected into 
ligated jejuno-ileal loop and after 10 min incubation the intestinal samples were prepared as 
described in Fig. 1. The preparations were co-stained with antibodies against cleaved caspase 
3. Scale bars = 10 µm.  
 
Supplementary Figure 3. Investigation of HCcB accumulating cells of the intestinal 
epithelium. HCcB-Cy3 (100 µg) was injected into ligated jejuno-ileal loop and after 10 min 
incubation the intestinal samples were prepared as described in Fig. 1. The preparations were 
co-stained with antibodies anti-ChAT (cholinergic cells), anti-chromogranin A 
(enteroendocrine cells), anti-M villous cell, anti-serotonin, anti-DCLK1 (tuft cells), anti-
WGA (goblet cells), anti-CD3 (T lymphocytes), anti-CD11C (dendritic cells) (green). 
Hoechst (blue). Scale bars = 20 µm. 
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Supplementary Figure 4.  Cells of the intestinal epithelium which accumulated HCcB, were 
not immunoreactive with antibodies ITF and cytokeratin18 specific of goblet cells. HCcB-
Cy3 (100 µg) was injected into mouse ligated jejuno-ileal loop. After 10 min incubation the 
intestinal samples were prepared as described in Fig. 1. The preparations were co-stained with 
antibodies anti-ITF (green) or anti-cytokeratin18 (green), as well as anti E cadherin (ECCD2) 
(white) and Hoechst (blue). Scale bars = 10 µm. 
 
Supplementary Figure 5. The ganglioside GM1 does not impair HCcB entrys into the 
intestinal mucosa. HCcB-Cy3 (70 µg) was injected into ligated jejuno-ileal loop (A) or 
incubated with a 10-fold excess of GM1 for 20 min at room temperature prior to injection into 
intestinal loop (B). After 15 min incubation the intestinal samples were prepared as described 
in Fig. 1. 
 
Supplementary Figure 6. Visualization of fluorescent HCcB (10 µg) in the mouse 
intestine following its injection into the intestinal lumen. HCcB-Cy3 (10 µg) in Dulbecco’s 
modified Eagle’s medium was injected into ligated jejuno-ileal loop of anesthetized mice. 
After 20 min incubation the intestinal samples were prepared as described in Fig. 1. 
Preparations were co-stained with antibodies anti E-cadherin (ECCD2) and Hoechst (blue). 
Scale bars = 10 µm. 
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Protein injected 
intraluminally 
 
Neuronal marker Colocalization 
(Pearson's 
coefficient) 
Co-stained neuronal 
structures with HCcB 
or BoNT/B (%) 
Cy3-HCcB ChAT 0.310 ± 0.07 82.2 ± 3.8 
BoNT/B ChAT 0.314 ± 0.08 87 ± 2.5 
Cy3-HCcB serotonin 0.25 ± 0.09 25.8 ± 5.4 
BoNT/B serotonin 0.34 ± 0.08 34.7 ± 6.9 
Cy3-HCcB VIP 0.294 ± 0.13 10.0 ± 1.6 
Cy3-HCcB V-GLUT 0.58 ± 0.09 56.2 ± 7.4* 
Cy3-NCcB V-GAT 0.24 ± 0.07 100 ± 14* 
 
 
Table 1. Quantification of colocalization between Cy3-HCcB or BoNT/B and neuronal 
markers in mouse submucosa and musculosa. Colocalization index was determined as 
Pearson's coefficient. The distribution of neuronal cells recognized by HCcB or BoNT/B was 
expressed as the ratio of the number of neuronal structures co-stained with HCcB or BoNT/B 
and with one neuronal marker to the total number of neuronal structures labeled with the 
corresponding neuronal marker. Results represent means ± SD accounting for at least 100 
cells from five different experiments except for V-GLUT and V-GAT (*) the results of which 
represent only a few cells (< 10).  
 
 
